ABX464-910
11 evidence topics · 3 sources
Objective
Location and study date
Trial dates and status in the EU register
| Field | Register entry |
|---|---|
| Protocol code | “Protocol code: ABX464-910” |
| Location | “Locations Belgium” |
| Start of trial | “Start of trial 10/10/2023” |
| End of trial | “End of trial 31/08/2024” |
Study design
Phase 1 drug-drug interaction design
Drug-drug interaction trials described in the Form 20-F
Eligibility criteria
Participant type and age in the EU register
| Field | Register entry |
|---|---|
| Medical condition | “Medical condition(s) Healthy female participants of childbearing potential.” |
| Participants type | “Participants type Healthy volunteers” |
| Age range | “Age range 18-64 years” |
Treatment
Multiple doses of obefazimod with ethinyl estradiol and drospirenone
Study outcomes
Rationale for using combined oral contraceptive pharmacokinetics as the study endpoint
No evidence found.
Statistical analysis description
Number of participants (Planned and analyzed)
Planned participants in the EU register
Enrollment in the two drug-drug interaction trials stated in the Form 20-F
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
Not applicable.
Safety results
No evidence found.
Study limitations
Summary
ABX464-910 has only an EU register record and a sentence in the Form 20-F, which does not name the trial by protocol number. The register gives the title, the dates (10 October 2023 to 31 August 2024), one site in Belgium, and 36 planned healthy women of childbearing potential aged 18 to 64 years. The doses, sampling schedule, endpoints, and the hormone measured are not public, and the summary of results is deferred until 28 February 2027. The 20-F states that the two drug-drug interaction trials were completed in 2025, whereas the register gives 31 August 2024 as the end of this trial. No pharmacokinetic or safety result has been published, so the effect of obefazimod on contraceptive exposure is unknown from public sources.